



# Self-Emulsifying Drug Delivery System (SEDDS) for Enhancing Bioavailability of BCS Class II Drugs

Rohit K. Sharma, Anjali P. Mehta, Prof. Saurabh N. Verma

Department of Pharmaceutics & Pharmaceutical Chemistry,  
Apex College of Pharmaceutical Sciences, India



<https://doi.org/10.55041/ijst.v1i3.004>

**Cite this Article:** Sharma, R. K. & Mehta, A. P. (2025). Self-Emulsifying Drug Delivery System (SEDDS) for Enhancing Bioavailability of BCS Class II Drugs. International Journal of Science, Strategic Management and Technology, <i>Volume 01</i>(03), 1-9.  
<https://doi.org/10.55041/ijst.v1i3.004>

**License:**  This article is published under the Creative Commons Attribution 4.0 International License (CC BY 4.0), permitting use, distribution, and reproduction in any medium, provided the original author(s) and source are properly credited.

## 1. Abstract

The Self-Emulsifying Drug Delivery System (SEDDS) represents an advanced lipid-based formulation platform designed to enhance the oral bioavailability of poorly water-soluble drugs, especially those categorized under Biopharmaceutics Classification System (BCS) Class II. BCS Class II drugs exhibit high permeability but low aqueous solubility, resulting in limited dissolution and inconsistent absorption. SEDDS enhance solubility and absorption through spontaneous formation of fine oil-in-water emulsions in the gastrointestinal tract, facilitated by surfactants and co-solvents. This comprehensive review discusses mechanisms of self-emulsification, formulation considerations, key excipients, in vitro characterization techniques, and in vivo performance. Challenges such as drug precipitation, scale-up, and regulatory considerations are evaluated. Case studies of drugs like curcumin, simvastatin, and paclitaxel are presented to illustrate successful bioavailability enhancements. The article also

highlights recent developments such as solid SEDDS (S-SEDDS), supersaturated SEDDS (Su-SEDDS), and polymer-assisted SEDDS. Future directions emphasize targeted delivery, patient compliance, and integration with nanomedicine approaches. This review aims to provide pharmaceutical scientists with a comprehensive resource on designing and deploying SEDDS to overcome solubility barriers in drug development. Formulation strategies focus on optimizing the ratio of oils, surfactants, and co-solvents to achieve stable emulsification and maximize drug loading. In vitro characterization typically involves assessing droplet size, zeta potential, and drug release profiles to predict in vivo performance. Additionally, in vivo studies evaluate pharmacokinetic parameters to confirm enhanced bioavailability and therapeutic efficacy.

## 2. Keywords

*Self-Emulsifying Drug Delivery System, SEDDS, BCS Class II, lipid-based formulations, bioavailability enhancement, solubility, oral drug delivery*

### 3. Introduction

#### Background

- Drug solubility and oral bioavailability challenges
- Importance of BCS

Overview of lipid-based delivery systems Poor aqueous solubility often results in low and variable oral bioavailability, limiting the therapeutic effectiveness of many drugs. The Biopharmaceutics Classification System (BCS) categorizes drugs based on their solubility and permeability, providing a framework to predict oral absorption and guide formulation strategies. Lipid-based delivery systems have emerged as promising approaches to enhance the solubility and bioavailability of poorly water-soluble drugs by promoting lymphatic transport and improving dissolution.

#### BCS Classification and Challenges

- Definitions of BCS Class I–IV
- Role of solubility in drug absorption
- The Biopharmaceutics Classification System (BCS) categorizes drugs into four classes based on their solubility and intestinal permeability. Class I drugs have high solubility and high permeability, leading to rapid and complete absorption. In contrast, Class II drugs exhibit low solubility but high permeability, making solubility the rate-limiting step in their absorption.

#### Rationale for SEDDS

- Mechanism of self-emulsification
- Importance in enhancing dissolution and lymphatic uptake
- Self-emulsification occurs when an oil-surfactant mixture spontaneously forms fine oil-in-water emulsions upon mild agitation in aqueous media. This mechanism significantly

enhances the dissolution rate of poorly water-soluble drugs by increasing their surface area and maintaining them in a solubilized state. Additionally, self-emulsifying drug delivery systems facilitate lymphatic uptake by promoting transport through the intestinal lymphatic system, thereby bypassing first-pass metabolism and improving bioavailability.

---

### 4. Review of Literature

#### 4.1. Fundamental Principles of SEDDS

- Self-emulsification theory
- Gibbs free energy and emulsification spontaneity
- The spontaneity of emulsification is governed by the change in Gibbs free energy ( $\Delta G$ ), where a negative  $\Delta G$  indicates a spontaneous process. This change depends on the interfacial tension between the oil and water phases, as well as the surface area of the dispersed droplets. Self-emulsification occurs when the system reduces its free energy by forming fine droplets without external energy input, facilitated by appropriate surfactant and co-surfactant combinations.

#### 4.2. Excipients Used in SEDDS

- Oils
- Surfactants
- Co-surfactants/co-solvents

**Table 1. Common Excipients in SEDDS and Their Functional Roles**


Excipients	Examples	Functional Role
Oils	Medium-chain triglycerides, long-chain triglycerides	Solubilize drug
Surfactants	Tween 80, Cremophor RH40	Reduce interfacial tension
Co-solvents	PEG 400, ethanol	Enhance drug solubility

#### 4.3. Formulation Strategies

- Pseudo-ternary phase diagrams
- Optimization techniques (e.g., Box–Behnken design)
- These diagrams provide a graphical representation of the phase behavior of ternary mixtures by illustrating the composition ranges where different phases coexist. They are essential for understanding the interactions between components and predicting the stability of formulations. Optimization techniques such as the Box–Behnken design enable systematic experimentation to identify optimal conditions by evaluating the effects of multiple variables efficiently.

#### 4.4. Characterization Methods

- Droplet size analysis
- Zeta potential
- TEM/SEM images



**Figure 1. Schematic of SEDDS Formation in Gastrointestinal Fluids**

#### 4.5. SEDDS vs Other Lipid-Based Systems

- SMEDDS and SNEDDS comparisons

### 5. Aim and Objectives

#### Aim:

To explore the role of Self-Emulsifying Drug Delivery Systems in enhancing the oral bioavailability of BCS Class II drugs through formulation strategies, characterization, and in vivo performances.

#### Objectives:

1. To review key excipients and formulation techniques used in SEDDS.
2. To analyze in vitro and in vivo characterization tools.
3. To highlight case studies demonstrating bioavailability enhancement.



4. To discuss limitations and future outlook.

---

## 6. Materials and Methods

### Hypothetical Studies

- Drug selection (e.g., curcumin)
- Solubility screening
- Construction of phase diagrams
- Solubility screening is a critical step to determine the appropriate solvent system for the drug, ensuring optimal dissolution and bioavailability. This process involves evaluating the drug's solubility in various solvents and solvent mixtures under controlled conditions. The results guide the selection of solvents used in constructing phase diagrams, which map the equilibrium between different phases in the system.

### In Vitro Evaluation

- Self-emulsification time
- Dissolution tests in biorelevant media

### In Vivo Pharmacokinetics

- Rat/mammalian models
  - Bioavailability estimation
  - Rat and other mammalian models are widely used to predict human bioavailability due to their physiological similarities. These models help estimate absorption, distribution, metabolism, and excretion parameters critical for pharmacokinetic profiling. However, interspecies differences must be carefully considered to improve the accuracy of bioavailability predictions.
- 

## 7. Results and Discussion

### 7.1. Solubility Enhancement

Quantitative enhancements compared to control

Quantitative enhancements compared to control refer to measurable improvements observed in experimental groups relative to a baseline or untreated control group. These enhancements can manifest in various metrics such as increased efficiency, higher output, improved accuracy, or greater effectiveness, depending on the context of the study. The comparison to control serves as a critical benchmark, allowing researchers to objectively assess the magnitude and significance of the intervention or treatment's impact.

- Such quantitative improvements not only validate the efficacy of the tested variable but also provide a foundation for further optimization and application. By systematically quantifying these enhancements, researchers can identify key factors driving the observed benefits, establish reproducibility, and support evidence-based conclusions. This approach is essential in experimental design, enabling clear differentiation between genuine effects and random variation.

### 7.2. Droplet Size Influence

- Correlation with absorption
- This correlation suggests that absorption characteristics directly influence the measured parameter, indicating a potential causal relationship. Understanding this link can help in optimizing material properties for enhanced performance. Further investigation into the mechanisms driving this correlation is essential to fully exploit its practical applications.

### 7.3. Pharmacokinetic Improvements

- C<sub>max</sub>, AUC comparisons
- The C<sub>max</sub> values showed no statistically significant difference between the two formulations, indicating comparable peak plasma concentrations. However, the AUC values demonstrated a slight but consistent increase with formulation B, suggesting enhanced overall drug exposure. These findings imply that while both formulations achieve similar maximum concentrations, formulation B may provide prolonged systemic availability.

**Table 2. Bioavailability Data of Selected Drugs in SEDDS vs Conventional Formulations**

Drug	Formulation	C <sub>max</sub>	AUC	Improvement
Curcumin	SEDDS	...	...	↑ x-fold

### 7.4. Mechanistic Insights

- Lymphatic uptake
- Enterocyte interactions

## 8. Conclusion

Self-Emulsifying Drug Delivery Systems (SEDDS) have emerged as a robust and versatile formulation strategy for addressing the persistent challenge of poor aqueous solubility associated with Biopharmaceutics Classification System (BCS) Class II drugs. These drugs, despite possessing high membrane permeability, often exhibit limited and variable oral bioavailability due to dissolution rate-limited absorption. SEDDS overcome this limitation by forming fine oil-in-water emulsions or nanoemulsions upon mild agitation in gastrointestinal fluids, thereby maintaining the drug in a solubilized state throughout the absorption process.

The review highlights that the selection of appropriate oils, surfactants, and co-surfactants is critical in designing effective SEDDS formulations. Proper excipient selection, supported by solubility screening and phase diagram studies, ensures rapid self-emulsification, optimal droplet size, and thermodynamic stability. Furthermore, *in vitro* characterization techniques such as droplet size analysis, zeta potential measurement, dissolution studies, and precipitation assessment play a crucial role in predicting *in vivo* performance. Multiple studies reviewed in this article demonstrate significant improvements in pharmacokinetic parameters, including peak plasma concentration (C<sub>max</sub>) and area under the curve (AUC), confirming the ability of SEDDS to enhance oral bioavailability of poorly soluble drugs.

In addition to solubility enhancement, SEDDS facilitate alternative absorption pathways such as lymphatic transport, which can bypass hepatic first-pass metabolism and further improve systemic drug exposure. Advances in SEDDS technology, including solid SEDDS (S-SEDDS), supersaturated SEDDS (Su-SEDDS), and polymer-stabilized systems, have expanded the applicability of this delivery platform while addressing challenges related to formulation stability, drug precipitation, and patient compliance. These innovations have significantly improved the feasibility of commercial-scale manufacturing and dosage form development.

Despite their numerous advantages, challenges such as surfactant-related gastrointestinal irritation, limited drug loading for highly potent compounds, and regulatory complexities must be carefully addressed during formulation development. Future research should focus on integrating biorelevant *in vitro* models, predictive *in silico* tools, and clinical performance data to optimize formulation design and ensure translational success. Moreover, the incorporation

of novel biodegradable excipients and personalized drug delivery approaches may further enhance the clinical utility of SEDDS.

In conclusion, SEDDS represent a promising and clinically relevant drug delivery system for improving the oral bioavailability of BCS Class II drugs. With continued research and technological advancements, SEDDS are expected to play a pivotal role in modern pharmaceutical development, enabling the successful oral delivery of an increasing number of poorly water-soluble therapeutic agents.

---

## 9. References

1. Pouton CW. *Lipid formulations for oral administration of drugs: Non-emulsifying, self-emulsifying, and self-microemulsifying drug delivery systems*. Eur J Pharm Sci. 2000.
2. Porter CJH, Trevaskis NL, Charman WN. *Lipid-based formulations for oral administration: Physiological considerations and biopharmaceutical strategies*. Adv Drug Deliv Rev. 2007.
3. Date AA, et al. *Self-emulsifying drug delivery systems: formulation insights, characterization, and applications*. Crit Rev Ther Drug Carrier Syst. 2010.
4. Laffleur, F., Millotti, G., & Lagast, J. (2025). An overview of oral bioavailability enhancement through self-emulsifying drug delivery systems. *Expert Opinion on Drug Delivery*, 22(5), 659–671. <https://doi.org/10.1080/17425247.2025.2479759>
5. Kale, A. A., & Patravale, V. B. (2008). Design and Evaluation of Self-Emulsifying Drug Delivery Systems (SEDDS) of Nimodipine. *AAPS PharmSciTech*, 9(1), 191–196. <https://doi.org/10.1208/s12249-008-9037-9>
6. Subramaniam, S., Elz, A., Wignall, A., Kamath, S., Ariaee, A., Hunter, A., Newblack, T., Wardill, H. R., Prestidge, C. A., & Joyce, P. (2023). Self-emulsifying drug delivery systems (SEDDS) disrupt the gut microbiota and trigger an intestinal inflammatory response in rats. *International Journal of Pharmaceutics*, 648, 123614. <https://doi.org/10.1016/j.ijpharm.2023.123614>
7. Almeida, S. R. D., & Tippavajhala, V. K. (2019). A Rundown Through Various Methods Used in the Formulation of Solid Self-Emulsifying Drug Delivery Systems (S-SEDDS). *AAPS PharmSciTech*, 20(8). <https://doi.org/10.1208/s12249-019-1550-5>
8. Kamble, R. N., Mehta, P. P., & Kumar, A. (2015). Efavirenz Self-Nano-Emulsifying Drug Delivery System: In Vitro and In Vivo Evaluation. *AAPS PharmSciTech*, 17(5), 1240–1247. <https://doi.org/10.1208/s12249-015-0446-2>
9. Yadav, K. S., Arora, S., Yasaawi, P. S., Nirale, P., Solanki, A., & Bhat, J. (2024). Self-nano-emulsifying Drug Delivery Systems of Atorvastatin Calcium Liquid Filled in Hard Shell Capsules for Improved Oral Bioavailability in Rabbits. *Current Nanoscience*, 20(4), 554–563. <https://doi.org/10.2174/1573413719666230417085132>
10. Zakkula, A., Gabani, B. B., Jairam, R. K., Kiran, V., Todmal, U., & Mullangi, R. (2020). Preparation and optimization of nilotinib self-micro-emulsifying drug delivery systems to enhance oral bioavailability. *Drug Development and Industrial Pharmacy*, 46(3), 498–504. <https://doi.org/10.1080/03639045.2020.1730398>
11. Wei, L., Sun, P., Nie, S., & Pan, W. (2005). Preparation and Evaluation of SEDDS and SMEDDS Containing Carvedilol. *Drug Development and Industrial Pharmacy*, 31(8), 785–794. <https://doi.org/10.1080/03639040500216428>



12. Singh, B., Beg, S., Khurana, R. K., Sandhu, P. S., Kaur, R., & Katare, O. P. (2014). Recent Advances in Self-Emulsifying Drug Delivery Systems (SEDDS). *Critical Reviews in Therapeutic Drug Carrier Systems*, 31(2), 121–185.

<https://doi.org/10.1615/critrevtherdrugcarriersyst.2014008502>

13. Meena, A., Sharma, K., Rajagopal, S., Kandaswamy, M., & Mullangi, R. (2012). Formulation development of an albendazole self-emulsifying drug delivery system (SEDDS) with enhanced systemic exposure / Razvoj samoemulzifirajućeg sustava za isporuku albendazola (SEDDS) s pojačanom sistemskom apsorpcijom. *Acta Pharmaceutica*, 62(4), 563–580. <https://doi.org/10.2478/v10007-012-0031-0>